

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:

File Information Unit, Room 2E04

2900 Crystal Drive

Arlington, VA 22202-3514

Telephone: (703) 308-2733

In re Application of

Application Number

Filed

08/112848

OCT/2/1996

OCT 29 2008

Paper No. 35

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____

United States Patent Number 6150584, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____

Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

Signature

Date

Typed or printed name

FOR PTO USE ONLY

Registration Number, if applicable

RECEIVED

Approved by:

(initials)

Unit

Telephone Number

File Information Unit

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006150584A

United States Patent [19]**Kucherlapati et al.**[11] **Patent Number:** **6,150,584**[45] **Date of Patent:** **Nov. 21, 2000**[54] **HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENOMICE**[75] Inventors: **Raju Kucherlapati**, Darien, Conn.; **Aya Jakobovits**, Menlo Park, Calif.; **Daniel G. Brenner**, Redwood City, Calif.; **Daniel J. Capon**, Hillsborough, Calif.; **Sue Klapholz**, Stanford, Calif.[73] Assignee: **Abgenix, Inc.**, Fremont, Calif.[21] Appl. No.: **08/724,752**[22] Filed: **Oct. 2, 1996****Related U.S. Application Data**

[63] Continuation-in-part of application No. 08/430,938, Apr. 27, 1995, abandoned, which is a continuation-in-part of application No. 08/234,143, Apr. 28, 1994, abandoned, and a continuation-in-part of application No. 08/112,848, Aug. 27, 1993, abandoned, and a continuation-in-part of application No. 08/031,801, Mar. 15, 1993, and a continuation-in-part of application No. 07/919,297, Jul. 24, 1992, abandoned, and a continuation-in-part of application No. 07/610,515, Nov. 8, 1990, abandoned, and a continuation-in-part of application No. 07/466,008, Jan. 12, 1990, abandoned, and a continuation-in-part of application No. PCT/US96/05928, Apr. 29, 1996.

[51] **Int. Cl.**⁷ **A61K 48/00**; C12N 5/10;
C12N 15/07[52] **U.S. Cl.** **800/18**; 800/6; 800/25;
424/93.21[58] **Field of Search** 800/2, 6, 25, 18;
424/93.21[56] **References Cited****U.S. PATENT DOCUMENTS**

4,950,599	8/1990	Bertling	435/456
4,959,313	9/1990	Taketo	435/69.1
5,204,244	4/1993	Fell et al.	435/68
5,545,806	8/1996	Lonberg et al.	800/6
5,545,807	8/1996	Surani et al.	800/6
5,569,825	10/1996	Lonberg et al.	800/18

FOREIGN PATENT DOCUMENTS

0 298 807 A1	6/1988	European Pat. Off.	
0 315 062 B1	5/1989	European Pat. Off.	
0 322 240 B1	6/1989	European Pat. Off.	
0 459 372 A3	5/1991	European Pat. Off.	
0 463 151 B1	1/1992	European Pat. Off.	
WO 90/04036	4/1990	WIPO	
WO 91/00906	1/1991	WIPO	
WO 91/10741	7/1991	WIPO	
WO 92/03918	3/1992	WIPO	
WO 93/05165	3/1993	WIPO	C12N 15/87
WO94/00569	1/1994	WIPO	C12N 15/00
WO 94/02602	2/1994	WIPO	

OTHER PUBLICATIONS

Patent Abstracts of Japan, vol. 13, No. 186 (E-752) (3534), May 2, 1989 Japanese Application 63-11 1378 (Hitachi).

Patent Abstracts of Japan, vol. 13, No. 254 (E-772) (3602), Jun. 13, 1989 Japanese Appln. 63-151680 (Sumitomo Electric).

Japanese Patent Abstract of Japan, vol. 6, No. 95(E-110) (973), Jun. 3, 1982, Japanese Appln. 57-27079 (Nippon Denshin).

Wu et al., "High Temperature Processing of Cuprate Oxide Superconductors" *Applied Physics Letters*, vol. 52, No. 22, May 30, 1988.

Patent Abstracts of Japan, vol. 13, No. 144 (E-740) (3492), Apr. 10, 1989 Japanese Application 63-306676 (Matsushita Electric).

Albertson, et al., "Construction and characterization of a yeast artificial chromosome library containing seven haploid human genome equivalents," *Proc. Natl. Acad. Sci. U.S.A.* 87:4256-4260 (1990).Ayares, et al., "Sequence homology requirements for inter-molecular recombination in mammalian cells," *Proc. Natl. Acad. Sci. U.S.A.* 83:5199-5203 (1986).Berman, et al., "Content and organization of the human Ig V_H locus: definition of three new V_H families and linkage to the Ig C_H locus" *EMBO J* 7:727-738 (1988).Blankenstein, et al., "Immunoglobulin V_H region genes of the mouse are organized in overlapping clusters" *Eur. J. Immunol.* 17:1351-1357 (1987).Brinster, et al., "Introns increase transcriptional efficiency in transgenic mice," *Proc. Natl. Acad. Sci. U.S.A.* 85:836-840 (1988).Brownstein, et al., "Isolation of single-copy human genes from a library of yeast artificial chromosomes," *Science* 244:1348-1351 (1989).Bruggemann, et al., "Construction, function and immunogenicity of recombinant monoclonal antibodies," *Behring Inst. Mitt.* 87:21-24 (1990).Bruggemann, et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," *Eur. J. Immunol.* 21:1323-1326 (1991).Bruggemann, et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," *Proc. Natl. Acad. Sci. U.S.A.* 86:6709-6713 (1989).Burke, et al., "Cloning of large segments of exogenous DNA into yeast by means of artificial chromosome vectors," *Science* 236:806-812 (1987).Buttin, et al., "Exogenous Ig rearrangement in transgenic mice: a new strategy for human monoclonal antibody production," *Trends in Genetics* 3(8):205-206 (1987).Davies, et al., 1992, "Targeted alterations in yeast artificial chromosomes for inter-species gene transfer," *Nucleic Acids Res.* 20:2693-2698 (1992).

(List continued on next page.)

Primary Examiner—Karen M. Hauda**Attorney, Agent, or Firm**—Fish & Neave; James F. Haley, Jr.; Jane T. Gunnison[57] **ABSTRACT**

Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.

12 Claims, 18 Drawing Sheets

#35